The Motley Fool

AUGUST 3, 2023

The second quarter of 2023 marked our two-year anniversary as a public company, and I'm extremely proud to announce we have exceeded consensus estimates and raised our outlook every quarter since we've gone public with Q2 continuing this pattern. Good afternoon everyone, and thank you for joining us today.

Leveraging 246

Leveraging Banks Capital Companies 246

The Motley Fool

FEBRUARY 15, 2024

Over the same 10 fiscal years, we've grown company revenue at a compound rate of over 13%, non-GAAP EPS at nearly 30%, free cash flow at 33%, and dividends per share at nearly 12%. Also, over this period, we increased return on invested capital from 8% to 35% and reduced net shares outstanding by over 30%. or Europe?

Banks 130

Banks Portfolios Companies Shareholders 130

The Motley Fool

MAY 8, 2024

This is really their first big public company transaction. And how do we think about return on invested capital for an investment like this? Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has a disclosure policy.

Assets 130

Assets Capital Returns Leveraging 130

The Motley Fool

MARCH 12, 2024

We will also offer some perspective on our strengthened balance sheet position with the recent divestiture of one of our noncore businesses, which underscores our focused product strategy and our commitment to driving a strong return on invested capital. The operating loss for the full year 2023 was $97.7 million in total.

Leveraging 130

Leveraging Accounting Capital Debt 130

The Motley Fool

NOVEMBER 1, 2023

Marketing budgets must be tied to measurable outcomes that generate a strong verifiable return on investment, which Zeta delivers. We're seeing messaging connected to CTV, and we're seeing messaging connected to social, both of which are very, very powerful when you look at the return on investment through our use case capabilities.

Professional Services 100

Professional Services Leveraging Capital Companies 100

The Motley Fool

FEBRUARY 5, 2024

We introduce this service because we know security teams are stretched thin, and MDDR builds upon automation enabled by the SaaS platform and maximizes their return on investment. listed public companies have raised awareness for cybersecurity, and we believe Varonis is well positioned to help companies comply with these regulations.

Securities and Exchange Commission (SEC) 130

Securities and Exchange Commission (SEC) Leveraging Capital Companies 130

The Motley Fool

AUGUST 4, 2023

Now that we've completed our two spinoffs, we have more opportunities to invest in driving long-term growth in LTL, a business that generates a high return on invested capital. We're also continuing to make strategic investments in our network to capitalize on upturns in demand. years from 5.9 years at the end of 2022.

Capital 130

Capital Depreciation Leveraging Companies 130

The Motley Fool

FEBRUARY 27, 2024

Our commitment to maintaining our financial flexibility and taking advantage of attractive return capital growth opportunities that complement our now larger and more diverse operating footprint continues to be the highest priority in our capital allocation strategy. Now, moving on to 2024 guidance. billion and EPS midpoint of $4.88

Mergers and Acquisitions 130

Mergers and Acquisitions Capital Assets Returns 130

The Motley Fool

OCTOBER 31, 2023

We have a high bar for the financial profile of acquisition targets, and we're pleased that Moritex clears this hurdle to contribute top-line growth and operating margins consistent with our overall company targets. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

Securities and Exchange Commission (SEC) 100

Securities and Exchange Commission (SEC) Capital Amortization Leveraging 100

The Motley Fool

AUGUST 9, 2023

It's no secret that I had hoped to move faster and at times it's been very frustrating given that we're both public companies and the benefits of our specific combination are so very clear. However, what's more eye opening for us is the market that the average return on investment for a new drug is just 1.2%.

Capital 100

Capital Mergers and Acquisitions Shareholders Companies 100